Prognostic Value of Nonangiogenic and Angiogenic Growth Patterns in Non-small-cell Lung Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2004 Aug 26

PMID 15328525

Citations 8

Authors

P Sardari Nia

C Colpaert

B Blyweert

B Kui

P Vermeulen

M Ferguson

J Hendriks

J Weyler

F Pezzella

E Van Marck

P Van Schil

Affiliations

Soon will be listed here.

Abstract

An essential prerequisite of nonangiogenic growth appears to be the ability of the tumour to preserve the parenchymal structures of the host tissue. This morphological feature is visible on a routine tissue section. Based on this feature, we classified haematoxylin and eosin-stained tissue sections from 279 patients with non-small-cell lung cancer into three growth patterns: destructive (angiogenic; n=196), papillary (intermediate; n=38) and alveolar (nonangiogenic; n=45). A Cox multiple regression model was used to test the prognostic value of growth patterns together with other relevant clinicopathological factors. For overall survival, growth pattern (P=0.007), N-status (P=0.001), age (P=0.020) and type of operation (P=0.056) were independent prognostic factors. For disease-free survival, only growth pattern (P=0.007) and N-status (P<0.001) had an independent prognostic value. Alveolar (hazard ratio=1.825, 95% confidence interval=1.117-2.980, P=0.016) and papillary (hazard ratio=1.977, 95% confidence interval=1.169-3.345, P=0.011) growth patterns were independent predictors of poor prognosis. The proposed classification has an independent prognostic value for overall survival as well as for disease-free survival, providing a possible explanation for survival differences of patients in the same disease stage.

Citing Articles

Vascular co-option in resistance to anti-angiogenic therapy.

Ribatti D, Annese T, Tamma R Front Oncol. 2023; 13:1323350.

PMID: 38148844 PMC: 10750409. DOI: 10.3389/fonc.2023.1323350.

Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer.

Cunningham C, Bolcaen J, Bisio A, Genis A, Strijdom H, Vandevoorde C Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259367 PMC: 9961924. DOI: 10.3390/ph16020219.

Overview on the Different Patterns of Tumor Vascularization.

Ribatti D, Pezzella F Cells. 2021; 10(3).

PMID: 33805699 PMC: 8000806. DOI: 10.3390/cells10030639.

Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma.

Yagi Y, Aly R, Tabata K, Barlas A, Rekhtman N, Eguchi T J Thorac Oncol. 2019; 15(4):589-600.

PMID: 31887430 PMC: 7288352. DOI: 10.1016/j.jtho.2019.12.112.

Vessel co-option in cancer.

Kuczynski E, Vermeulen P, Pezzella F, Kerbel R, Reynolds A Nat Rev Clin Oncol. 2019; 16(8):469-493.

PMID: 30816337 DOI: 10.1038/s41571-019-0181-9.

References

Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M . Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst. 1997; 89(12):881-6. DOI: 10.1093/jnci/89.12.881. View

Yano S, Nishioka Y, Goto H, Sone S . Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci. 2003; 94(6):479-85. PMC: 11160313. DOI: 10.1111/j.1349-7006.2003.tb01469.x. View

Sardari Nia P, Stessels F, Pezzella F, Vermeulen P, van Marck E, Van Schil P . Growth index is independent of microvessel density in non-small cell lung carcinomas. Hum Pathol. 2003; 34(9):959-60. DOI: 10.1016/s0046-8177(03)00247-8. View

Funai K, Yokose T, Ishii G, Araki K, Yoshida J, Nishimura M . Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol. 2003; 27(7):978-84. DOI: 10.1097/00000478-200307000-00013. View

Stessels F, Van den Eynden G, Van der Auwera I, Salgado R, van den Heuvel E, Harris A . Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer. 2004; 90(7):1429-36. PMC: 2409675. DOI: 10.1038/sj.bjc.6601727. View

Giatromanolaki A, Koukourakis M, Sivridis E, OByrne K, Gatter K, Harris A . 'Invading edge vs. inner' (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. J Pathol. 2000; 192(2):140-9. DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH693>3.0.CO;2-R. View

Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G . Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol. 1997; 15(8):2858-65. DOI: 10.1200/JCO.1997.15.8.2858. View

Koukourakis M, Giatromanolaki A, Thorpe P, Brekken R, Sivridis E, Kakolyris S . Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 2000; 60(11):3088-95. View

Cannistra S . When is a "prognostic factor" really prognostic?. J Clin Oncol. 2000; 18(22):3745-7. DOI: 10.1200/JCO.2000.18.22.3745. View

10.

Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S . Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995; 75(12):2844-52. DOI: 10.1002/1097-0142(19950615)75:12<2844::aid-cncr2820751209>3.0.co;2-#. View

11.

OByrne K, Koukourakis M, Giatromanolaki A, Cox G, Turley H, Steward W . Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer. 2000; 82(8):1427-32. PMC: 2363365. DOI: 10.1054/bjoc.1999.1129. View

12.

Vermeulen P, Sardari Nia P, Colpaert C, Dirix L, Marck E . Lack of angiogenesis in lymph node metastases of carcinomas is growth pattern-dependent. Histopathology. 2002; 40(1):105-7. DOI: 10.1046/j.1365-2559.2002.1340c.x. View

13.

Vermeulen P, Gasparini G, Fox S, Colpaert C, Marson L, Gion M . Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002; 38(12):1564-79. DOI: 10.1016/s0959-8049(02)00094-1. View

14.

Duarte I, Bufkin B, Pennington M, Gal A, Cohen C, Kosinski A . Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1998; 115(3):652-8; discussion 658-9. DOI: 10.1016/S0022-5223(98)70331-9. View

15.

Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M . Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res. 2002; 62(23):7124-9. View

16.

Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G . Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol. 1997; 151(5):1417-23. PMC: 1858069. View

17.

Folkman J . What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990; 82(1):4-6. DOI: 10.1093/jnci/82.1.4. View

18.

Offersen B, Pfeiffer P, Hamilton-Dutoit S, Overgaard J . Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer. 2001; 91(8):1500-9. View

19.

. Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Breast Cancer Progression Working Party. Lancet. 2000; 355(9217):1787-8. View

20.

Mountain C . Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111(6):1710-7. DOI: 10.1378/chest.111.6.1710. View